A CLINICAL STUDY ON LEVOFLOXACIN IN TREATMENT OF TONSILLITIS, PHARYNGITIS AND SIALADENITIS

We performed a clinical study of levofloxacin (LVFX, DR-3355) in patients with tonsillitis, pharyngitis and sialadenitis, and the following results were obtained. 1) The clinical efficacy rates were 91.7% for tonsillitis, 100% for peritonsillitis, 78.6% for pharyngitis and 81.8% for sialadenitis. 2)...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 40; no. Supplement3; pp. 352 - 364
Main Author Ohyama, Masaru
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1992
Subjects
Levofloxacin
Online AccessGet full text

Cover

More Information
Summary:We performed a clinical study of levofloxacin (LVFX, DR-3355) in patients with tonsillitis, pharyngitis and sialadenitis, and the following results were obtained. 1) The clinical efficacy rates were 91.7% for tonsillitis, 100% for peritonsillitis, 78.6% for pharyngitis and 81.8% for sialadenitis. 2) The bacterial eradication rates were 100% for monomicrobial infection cases and 86.7% for polymicrobial infection cases. 3) Adverse responses were observed in six (mainly upper gastrointestinal disorders) out of 103 patients, for an incidence of 5.8%. All of the symptoms were mild. Abnormal laboratory findings were recorded in three cases: elevated GOT in one case and elevated GPT in two cases. Based on these results, LVFX is surmised to be a safe and useful agent for the treatment of tonsillitis, pharyngitis and sialadenitis.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.40.Supplement3_352